According to researchers, responses to tisotumab vedotin were seen in women with refractory advanced cervical cancer.
Single-agent neratinib was associated with durable responses in a subcohort of women in the SUMMIT trial.
High expression of indoleamine 2.3-dioxygenase pathway genes correlated with the presence of immune escape mechanisms in ovarian cancers, according to researchers.
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
Researchers estimated cost effectiveness for first-line maintenance therapy with bevacizumab or olaparib in women with BRCA-mutant ovarian cancer.
According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.
Black women with locally advanced cervical cancer are significantly less likely to receive brachytherapy compared with non-black women with this disease.
In the QUADRA trial patients with low baseline platelet count or low body weight were more likely to experience grade 3/4 adverse events.
More data are needed regarding the efficacy and safety of administering multiple lines of PARP inhibitor therapy, according to researchers.
Simultaneous molecular characterization of paired germline and tumor specimens may gain importance as more targeted therapies become available.
Women aged 75 and older with advanced ovarian cancer enrolled in the phase 3 ARIEL3 trial were less likely to have deleterious germline or somatic BRCA mutations.
According to researchers, the Lymphadenectomy in Ovarian Neoplasms (LION) trial was meticulously designed to eliminate many potential confounding factors.
Epigenetic aberrations, as opposed to DNA mutations themselves, might play a more important role in the progression of many malignancies.
Lynparza, a poly (ADP-ribose) polymerase (PARP) inhibitor is already approved to treat certain breast, epithelial ovarian, fallopian tube or primary peritoneal cancers based on an FDA-approved companion diagnostic.
New findings conflict with earlier retrospective studies and the general consensus supporting the use of minimally invasive surgery in early-stage cervical cancer.
Olaparib maintenance therapy after platinum chemotherapy substantially prolonged PFS compared with placebo in newly diagnosed advanced ovarian cancer.
Patients in the real world setting were initiated at a lower dose and experienced fewer side effects than trial participants.
Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.
Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.
The US Preventive Services Task Force conducted a review of trials and cohort studies to support an update of its cervical cancer screening recommendations for women ages 21 to 65 and older.